Introduction
To better define the mechanisms of neuromodulation, we have carried out a genetic analysis of the inhibition G protein-coupled receptors often modulate synaptic and facilitation of neurotransmission in an in vivo sysstrength by regulating release of neurotransmitter from tem, the Caenorhabditis elegans neuromuscular juncnerve terminals. These neuromodulatory pathways can tion. We previously showed that goa-1 G o ␣ inhibits aceeither facilitate or inhibit neurotransmitter release (Nicoll tylcholine release at these synapses by reducing the et al., 1990). In some cases, neuromodulators regulate levels of UNC-13 at release sites (Nurrish et al., 1999) . synaptic transmission via regulation of presynaptic ion Here, we show that egl-30 G q ␣ and egl-8 phospholipase channels, particularly voltage-dependent Ca 2ϩ chan-C␤ (PLC␤) stimulate production of presynaptic diacylnels. N-type Ca 2ϩ currents are inhibited by a wide array glycerol (DAG), which facilitates neurotransmitter reof neuromodulators, at a wide range of synapses (Anwyl, lease at neuromuscular synapses, and that this effect 1991). Virtually all modulators that inhibit transmitter is mediated in part by UNC-13. Since UNC-13 directly release also inhibit Ca 2ϩ currents. Certain inwardly rectibinds to the target SNARE (soluble N-ethylmaleimidefied K ϩ channels (GIRKs) are also modulated by G prosensitive fusion protein attachment receptors) syntaxin tein-coupled receptors, but it is unclear if GIRK regulation (Betz et al., 1997), these results suggest that DAG diis utilized to modulate synaptic transmission (Lü scher et rectly regulates synaptic vesicle exocytosis at these al., 1997).
synapses. In other cases, neuromodulators are thought to directly regulate some aspect of synaptic vesicle recycling.
Results Neurotransmitter is released from nerve terminals by fusion of synaptic vesicle and presynaptic membranes egl-8 Encodes a PLC␤ (Scheller, 1995 (Figure 2A) . Similarly, locomotion observed in egl-8 mutants (Table 1) were we found that loss-of-function mutations in egl-8 PLC␤ similar to those reported for egl-30 G q ␣ reduction-ofproduced resistance to aldicarb in both acute and function alleles (Brundage et al., 1996), suggesting that chronic assays, which was corrected by expression of these genes might act in a common pathway. We found egl-8 PLC␤ transgenes (Figure 2 ; Table 1 ). Transient that transgenes containing B0348.3 corrected the egg expression of a constitutive, GTPase defective form of laying, defecation, and locomotion defects observed in egl-30 G q ␣(Q209L) with a heat shock vector made wildegl-8 mutants (Table 1) The residual effect of egl-30 G q ␣(Q209L) in egl-8 mutants sponds to a nonsense mutation in exon 2 and is therefore could reflect activation of other PLC␤ isoforms (three likely to produce a severe reduction in gene activity. others are predicted in the genome sequence), residual The n2659 mutation (G45D) alters a conserved residue activity of the egl-8(sa47) PLC␤, or activation of other in the pleckstrin homology (PH) domain, which is re-G q ␣ targets. Together, these results suggest that eglquired for binding to phosphatidylinositol bisphosphate 30 G q ␣ and egl-8 PLC␤ both regulate synaptic transmis-(PIP 2 ). These results demonstrate that the B0348.3 PLC␤ sion at neuromuscular junctions. corresponds to the egl-8 gene. These results also sugThe effects of egl-30 G q ␣ and egl-8 PLC␤ on synaptic gest that egl-8 alleles are loss-of-function mutations, as transmission could reflect either a change in the release they have a recessive pattern of heredity, their phenoof acetylcholine by motor neurons or a change in the types are corrected by expressing a wild-type egl-8 responsiveness of muscles to acetylcholine. To distintransgene, and their molecular nature is consistent with guish between these possibilities, we examined the efa reduction in gene activity. fects of egl-30 G q ␣ and egl-8 PLC␤ on the responsiveness of animals to levamisole, a potent agonist for G q ␣ and PLC␤ Regulate Acetylcholine the body muscle acetylcholine receptors (Fleming et al., Release at Neuromuscular Junctions 1997). We found that neither increased or decreased One model for regulation of locomotion by egl-30 G q ␣ activity of egl-30 G q ␣, or decreased activity of egl-8 and egl-8 PLC␤ is that these gene products modulate PLC␤, altered the response to levamisole ( Figure 2B ). synaptic transmission at neuromuscular junctions. To
In contrast, control animals lacking a muscle nicotinic test this possibility, we assayed synaptic release of aceacetylcholine receptor (UNC-29) were resistant to the tylcholine by measuring the sensitivity of animals to the paralytic effects of levamisole ( Figure 2B ). These results acetylcholinesterase inhibitor aldicarb (Figure 2 ). Aldisuggest that egl-30 G q ␣ and egl-8 PLC␤ do not decarb enhances the effects of endogenously released tectably alter the responsiveness of muscles to acetylacetylcholine, which is the neuromuscular transmitter choline but rather that they regulate the release of acefor locomotion (Rand and Nonet, 1997 If egl-30 G q ␣ and egl-8 PLC␤ act in the ventral cord not affected ( Figure 5A ). This effect of arecoline treatment was likely due to increased synaptic transmission motor neurons, then we would expect that expressing these genes with a motor neuron-specific promoter (deat neuromuscular junctions, since unc-29 mutants, which lack a muscle nicotinic acetylcholine receptor (Fleming rived from the acetylcholine receptor gene acr-2) should restore normal locomotion to mutants lacking these proet al., 1997), were resistant to treatment with both arecoline and aldicarb ( Figure 5D ). Arecoline-induced hyperteins. Expression of egl-8 PLC␤ with the acr-2 promoter restored normal locomotion rates (15.7 Ϯ 2 body bends sensitivity to aldicarb could not be explained by hyperresponsiveness of body wall muscles to acetylcholine, per minute) and aldicarb responsiveness to egl-8 mutants ( Figure 2D ). By contrast, expression of the GTPasesince arecoline did not alter responsiveness to the acetylcholine agonist levamisole ( Figure 2B ). Taken todefective, constitutively active mutant egl-30 G q ␣(Q209L) in motor neurons caused animals to become hypersensigether, these results suggest that the muscarinic agonist arecoline stimulates acetylcholine release at neuromustive to aldicarb ( Figure 2D ), consistent with an increase in acetylcholine release. In addition to these changes in cular junctions and that egl-30 G q ␣ is required for this effect. aldicarb sensitivity, expression of these transgenes in motor neurons altered locomotion behavior (Figure 4) ester (4␣-PMA) had no effect ( Figures 5B and 5C ). The stimulatory effect of phorbol esters was saturated at G q ␣ is required to mediate the effects of muscarinic agonists, e.g., arecoline, on pharyngeal pumping (Brundconcentrations Ͼ0.25 g/ml. This effect of phorbol ester treatment was likely due to increased synaptic transmisage et al., 1996). We found that exogenous arecoline caused wild-type animals to become hypersensitive to sion at neuromuscular junctions, since unc-29 mutants were resistant to treatment with both phorbol esters (2 aldicarb, whereas homozygous egl-30 G q ␣ mutants were g/ml) and aldicarb ( Figure 5D ). Phorbol ester-induced and egl-8 PLC␤ stimulates acetylcholine release at neuromuscular junctions. hypersensitivity to aldicarb could not be explained by hyperresponsiveness of body wall muscles to acetylcholine, since phorbol esters (2 g/ml) did not alter responsiveness to the acetylcholine agonist levamisole DAG Binding to UNC-13S Is Required for Stimulation of Acetylcholine Release (data not shown). Similarly, we found that treatment with phorbol esters (0.25 g/ml) restored aldicarb sensitivity One attractive candidate for the synaptic target of DAG is UNC-13, a presynaptic DAG-binding protein (Maruto homozygous egl-30 G q ␣ or egl-8(sa47) PLC␤ mutants ( Figure 5C) (Betz et al., 1997) . In addition, mutations in either snt-1 (synaptotagmin) or rab-3 UNC-13L has a domain that binds to UNC-18 (nSec-1) (Rab-3) are resistant to aldicarb (Nonet et al., 1993,  (Sassa et al., 1999) . We previously showed that expres-1997). Nonetheless, phorbol ester treatment (0.25 g/ml) sion of a GFP-tagged form of UNC-13S restored normal of snt-1 or rab-3 mutants caused hypersensitivity to locomotion rates and normal aldicarb responsiveness aldicarb that was similar to that observed in phorbolto homozygous unc-13(e51) mutants ( Figure 5E ; Nurrish treated wild-type animals ( Figure 5F ). Therefore, the reet al., 1999). Thus, UNC-13S activity is sufficient to reduced potency of phorbol esters observed in animals constitute synaptic transmission.
expressing UNC-13S(H173K)::GFP cannot be explained If UNC-13S were an important target of DAG at neuroby a general failure in synaptic vesicle exocytosis. Thus, muscular junctions, then mutations that prevent binding our results are most consistent with the idea that DAG of DAG to UNC-13S should act like mutations that elimibinding to UNC-13S is required for phorbol-induced nate UNC-13 function. To test this hypothesis, we constimulation of acetylcholine release. structed a mutant form of UNC-13S, H173K, in which we altered a conserved residue in the C1 domain. Histi-
Forced Membrane Association of UNC-13S dine 173 is conserved in all phorbol ester-binding C1

Compensates for Decreased domains (Hurley et al., 1997) and is required for coordi-
Production of DAG nating zinc ions (Zhang et al., 1995). A histidine-to-lysine DAG often activates its targets by promoting their assosubstitution at this position abolished phorbol ester ciation with membranes, and treatment with phorbol binding to the C1 domain of Munc13-1 (Betz et al., 1998), esters promotes membrane association of the mouse and other substitutions at this position abolished phorortholog Munc13-1 (Betz et al., 1998). These results bol ester binding to protein kinase C␦ (Kazanietz et al., suggested that the behavioral defects caused by de1995b). While expression of wild-type UNC-13S::GFP in
creased production of presynaptic DAG (e.g., in egl-8 homozygous unc-13 mutants appeared to fully restore PLC␤ mutants) are the consequence of a failure to prosynaptic function, expression of UNC-13S(H173K)::GFP mote association of UNC-13 with the plasma membrane produced an intermediate phenotype in which transat nerve terminals. We tested this possibility by congenic animals remained slightly uncoordinated and structing a constitutively membrane-bound form of slightly resistant to aldicarb (Figures 4 and 5E) . The wild-
UNC-13S (myrUNC-13S) that contains a consensus setype UNC-13S::GFP and UNC-13S(H173K)::GFP trans-
quence for amino-terminal myristoylation. Expression genes were equally well expressed (146 Ϯ 3 and 136 Ϯ of myrUNC-13S in mutants lacking egl-8 PLC␤ dramati-8 arbitrary fluorescence units, respectively); therefore, cally improved locomotion rate and aldicarb sensitivity the effect of the C1 domain mutation cannot be attrib-( Figure 5G ). These results demonstrate that forced memuted to a difference in expression level. These results brane association of UNC-13S partially compensates suggest that DAG binding is not essential for all aspects for the absence of egl-8 PLC␤, as would be expected of UNC-13S function but rather that DAG binding is likely to regulate the basal activity of UNC-13S. if UNC-13S were an important target for the DAG proThe C1 domain mutation (H173K) in UNC-13S altered duced by the egl-8 PLC␤. the dose-response relationship between phorbol esters and aldicarb sensitivity (Figures 5B and 5E ). Treatment egl-30 G q ␣ Regulates the Distribution of UNC-13S of animals expressing wild-type UNC-13S::GFP with eiin the Ventral Nerve Cord ther 2 or 0.25 g/ml PMA produced equivalent increases If egl-30 G q ␣ stimulates acetylcholine release by increasin aldicarb sensitivity. By contrast, in animals expressing ing the abundance of DAG in motor neurons, then we UNC-13S(H173K)::GFP, 0.25 g/ml PMA had no detectmight expect that egl-30 G q ␣ would regulate the subcelable effect, and 2 g/ml PMA had a reduced effect, lular distribution of UNC-13S in motor neurons. Consiscompared with wild-type controls. These results demontent with this idea, we previously showed that another strate that transgene-encoded UNC-13S is the primary GTP-binding protein, goa-1 G o ␣, inhibits acetylcholine phorbol receptor involved in facilitating synaptic transrelease by decreasing the abundance of UNC-13S at mission following 0.25 g/ml PMA treatment. One interneuromuscular junctions (Nurrish et al., 1999) . These pretation of these results is that a second, unidentified results suggested that if egl-30 G q ␣ produces a local low-affinity phorbol target accounts for the response to change in DAG levels at neuromuscular junctions, this high doses (2 g/ml) of phorbol esters. Interestingly, could be visualized by observing a change in the distriexpression of UNC-13S(H173K)::GFP reduced but did bution of UNC-13S in the ventral nerve cord following not eliminate the hypersensitivity to aldicarb caused by activation of egl-30 G q ␣.
expression of egl-30 G q ␣ (Q209L) (data not shown). This
We tested this idea by comparing the distribution of result is also consistent with the idea that UNC-13S is UNC-13S::GFP in the ventral nerve cords of untreated not the only target responsible for egl-30 G q ␣-mediated and arecoline-treated animals ( Figure 6 ; Table 2 ). As we stimulation of acetylcholine release. However, it remained possible that phorbol ester resistance in this previously showed (Nurrish et al., 1999) , in untreated 1993; Nonet et al., 1993 Nonet et al., , 1997 Nonet et al., , 1998 Nonet et al., , 1999 . Therefore, it is well established that reducing acetylcholine release Muscarinic agonists also stimulate acetylcholine release, and this effect requires the activity of egl-30 G q ␣.
confers resistance to aldicarb. We show here that other mutations (or drug treatments) cause hypersensitivity to Providing exogenous phorbol esters restores normal acetylcholine release to mutants lacking either egl-30 aldicarb, which we interpret as an increased release of 
